Sino Biopharmaceutical Partners with Sciwind for Innovative RSV Treatment

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.

Sino Biopharmaceutical Limited has signed an exclusive strategic cooperation agreement with Sciwind Biosciences for the development and licensing of the IL-29 project, known as CPX102, in 19 countries. CPX102 is a nebulized inhalation solution targeting respiratory syncytial virus (RSV) infections in children and is currently in Phase IIb clinical trials in China. This innovative treatment offers a broad-spectrum antiviral approach with potential applications for other respiratory viruses like SARS-CoV-2 and influenza. The agreement positions Sino Biopharmaceutical to potentially capture a significant market share in the respiratory/anti-infection field, addressing a large unmet clinical demand for effective RSV treatments.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company in the biopharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is involved in producing treatments for respiratory infections and other medical conditions, with a market focus that includes China and several other countries.

YTD Price Performance: 15.90%

Average Trading Volume: 1,574

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $8.28B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.